In Brief: Merck's Mectizan
Merck's Mectizan: Ivermectin oral 6 mg tablets approved Nov. 25 for treatment of strongyloidiasis of GI tract and onchocerciasis (river blindness), FDA announces Nov. 25. In controlled clinical trials, a single dose of ivermectin cured between 64% and 100% of patients infected with intestinal strongyloidiasis; in onchocerciasis patients, ivermectin reduced number of larvae in skin an average of 83.2% at three days and 99.5% at three months after a single dose, according to an FDA "Talk Paper." Mectizan was deemed "approvable" at FDA Oct. 8; Merck filed an NDA for the indications in March ("The Pink Sheet" Oct. 21, In Brief)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth